Giant cell arteritis is a systemic vasculitis and careful attention should be given to the examination of the cardiovascular system including performing blood pressure measurements in both arms.

Giant cell arteritis (GCA) is the most common form of vasculitis in the older adult population. There are variable clinical presentations of this entity and no perfect diagnostic test, often ...

Giant cell arteritis, or GCA, is a condition where arteries in the head and neck become inflamed. It is called ‘giant cell’ because abnormally large cells accumulate in the artery walls.

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Based Performance of Inflammatory Markers in Giant Cell Arteritis,” published in the March 2025 issue of American Journal of ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA. "Giant cell arteritis is an inflammatory disease that, if left untreated, can lead to severe ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Are you waking up in the morning with stiff hips, back and neck? You might want to get yourself checked for Polymyalgia Rheumatica (PMR). PMR is a condition characterized by inflammation that leads to ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

Patients in the EU with giant cell arteritis (GCA), an inflammation of the arteries, could soon have the first oral targeted treatment for the disease after AbbVie's Rinvoq was recommended for ...